Clinical trials: Malaria Transmission
Prevention of Malaria Transmission and Clinical Malaria
Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults
This is a Phase 2, randomized, double-blind, controlled study designed to evaluate the safety, tolerability, immunogenicity, vaccine efficacy, and functional activity of Pfs230D1-CRM197 conjugate vaccine with R21 nanoparticle…
- Trial name
- NCT07147400
- Testing
- 10µg of R21 with 50µg Matrix-M1, 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation, RABIVAX-S
- Where
- Mali
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Prevention of Malaria Transmission and Clinical Malaria
Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults
This is a Phase 1, individually randomized, double-blind, dose escalating study designed to evaluate the safety, tolerability, and immunogenicity of Pfs230D1 conjugate vaccines, R21 nanoparticle vaccine, or their combination…
- Trial name
- NCT06507605
- Testing
- R21, Pfs230D1-CRM197, Pfs230D1-EPA
- Where
- Mali
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Malaria Asymptomatic Parasitaemia, Malaria Falciparum
Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana
Previous malaria control studies in Ghana have shown that community-wide approaches can substantially reduce malaria infections.
- Conditions
- Malaria Asymptomatic Parasitaemia, Malaria Falciparum, Malaria Infection, Malaria Transmission
- Trial name
- NCT07389057
- Testing
- DHAP, Single low dose PQ
- Where
- Ghana
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Noguchi Memorial Institute for Medical Research
Malaria Transmission, Malaria Prevention
Long-acting Spatial Emanators / Repellents (LASER)
Malaria is a major problem in western Kenya, particularly around Lake Victoria. Whilst current prevention methods like bed nets and vaccines help to reduce malaria burden, additional tools are needed to better protect communities…
- Conditions
- Malaria Transmission, Malaria Prevention, Malaria
- Trial name
- LASER (NCT07387341)
- Testing
- Guardian, IRS with Pirimiphos - methyl
- Where
- Kenya
- Volunteers
- 22,815 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Malaria Falciparum, Malaria Infection
Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP
The goal of this clinical trial is to learn if the genetically-modified malaria parasite NF54/iGP3 will safely infect humans with malaria.
- Conditions
- Malaria Falciparum, Malaria Infection, Malaria Transmission
- Trial name
- iGP3-SWITCH (NCT06881732)
- Testing
- NF54/iGP3
- Where
- Australia
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- University of Melbourne
Controlled Human Malaria Infection, Induced Blood Stage Malaria Infection
In-vivo Transmission Model in Semi-immune Adults
Controlled human malaria infection (CHMI) has revolutionized the development of malaria vaccines. It involves the administration of either known numbers of sporozoites or infected erythrocytes to healthy human volunteers under a…
- Conditions
- Controlled Human Malaria Infection, Induced Blood Stage Malaria Infection, Malaria Transmission, Malaria Challenge
- Trial name
- NCT06172686
- Testing
- Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg)., Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.
- Where
- Tanzania
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ifakara Health Institute
Malaria, Malaria,Falciparum
Attractive Targeted Sugar Bait Phase III Trial in Zambia
The trial will evaluate the efficacy of ATSB deployment plus universal coverage of a WHO core vector control (VC) interventions over two transmission seasons on a minimum 30% reduction in cohort clinical disease incidence…
- Conditions
- Malaria, Malaria,Falciparum, Vector-Borne Transmission of Infection
- Trial name
- NCT04800055
- Testing
- Attractive Targeted Sugar Bait
- Where
- Zambia
- Volunteers
- 3,480 people, healthy volunteers welcome
- Sponsor
- PATH
Vector Transmission
Attractive Targeted Sugar Bait Trial in Mali
Globally, the female mosquitoes to be effective at transmitting malaria parasites, must have a number of characteristics including: abundance, longevity (individual mosquitoes must survive long enough after feeding on infected…
- Trial name
- NCT04149119
- Testing
- Attractive Target Sugar Baits (ATSB)
- Where
- Mali
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- University Clinical Research Center, Mali
Malaria Transmission
Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity
Assessing the effect of neglected tropical diseases on Plasmodium falciparum transmission in an area of co endemicity.
- Trial name
- TRANSMAL (NCT02769013)
- Testing
- Pre-treatment follow up, S. haematobium treatment, Post treatment follow up
- Where
- 2 sites in Gabon, Ghana
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Malaria,Falciparum, Gametocytes
Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2
This is a single-center, open label study. The primary aim of this project is to develop a controlled human malaria infection transmission model ("CHMI-trans") or "challenge model" to evaluate the capacity of vaccines, biologics…
- Conditions
- Malaria,Falciparum, Gametocytes, Controlled Human Malaria Infection, Transmission
- Trial name
- CHMI-trans2 (NCT03454048)
- Testing
- Piperaquine (low dose), Piperaquine (high dose), Sulfadoxine pyrimethamine
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Malaria Transmission
The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy
The investigators' Hypothesis is that "The correct timing of gametocytocidal drug in combination with an effective Artemisinin Combination Therapy can limit the infectiousness of malaria-infected individuals to less than one week…
- Trial name
- NCT01906788
- Testing
- Artemether Lumefantrine, Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0, Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
- Where
- Tanzania
- Volunteers
- 250 people
- Sponsor
- Kilimanjaro Clinical Research Institute